[Rituximab in the treatment of diffuse large B-cell lymphoma: The CACNA1C subunit of channel Cav1.2 expression linked to certain forms of resistance]
- PMID: 33908862
- DOI: 10.1051/medsci/2021043
[Rituximab in the treatment of diffuse large B-cell lymphoma: The CACNA1C subunit of channel Cav1.2 expression linked to certain forms of resistance]
References
-
- Li S , Young KH , Medeiros LJ . Diffuse large B-cell lymphoma. Pathology 2018 ; 50 : 74–87.
-
- Wästerlid T, Harrysson S, Andersson TM, et al. Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma. Am J Hematol 2020; 95 : 740–8.
-
- Smith MR . Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003 ; 22 : 7359–7368.
-
- Janas E , Priest R , Wilde JI , et al. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005 ; 139 : 439–446.
-
- Coiffier B , Thieblemont C , Van Den Neste E , et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010 ; 116 : 2040–2045.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources